Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

Core Insights - Senti Biosciences, Inc. presented positive Phase 1 data for its lead program SENTI-202 at the AACR Annual Meeting, indicating potential as a treatment for Acute Myeloid Leukemia (AML) with 4 out of 7 patients achieving composite Complete Remission (cCR) [1][3][4] - The company reported financial results for Q1 2025, showing a net loss of $14.1 million, with cash and cash equivalents of approximately $33.8 million as of March 31, 2025 [9][14] Clinical Data Highlights - SENTI-202 was well tolerated with no dose-limiting toxicities, and the preliminary recommended Phase 2 dose (RP2D) was identified as 1.5 x 10 CAR NK cells administered on Days 0, 7, and 14 in 28-day cycles [4] - All 4 patients who achieved cCR were measurable residual disease (MRD) negative, and responses have been maintained for follow-ups ranging from 4+ to 8+ months [1][4] - The ongoing enrollment in the Phase 1 study aims to confirm the RP2D and expand into disease-specific cohorts [1][3] Corporate Developments - The company is advancing its Logic-Gated cell therapy approach, which may have applications in both liquid and solid tumors, providing multiple pipeline expansion opportunities [1][2] - Senti Bio has joined the Webull Corporate Connect Service platform to enhance communication with shareholders and increase market visibility [5] Financial Overview - Research and development expenses for Q1 2025 were $9.3 million, an increase from $8.8 million in Q1 2024, primarily due to higher external services costs [9][14] - General and administrative expenses decreased to $7.1 million in Q1 2025 from $7.5 million in Q1 2024 [9][14] - The total operating expenses for the quarter were $16.4 million, slightly up from $16.3 million in the same period last year [9][14]